Delve into the intricate world of nodal peripheral T-cell lymphomas as we unravel the latest insights into their pathobiology and explore the promising horizons for future research and treatment strategies.
– by Marv
Note that Marv is a sarcastic GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Pathobiology of nodal peripheral T-cell lymphomas: current understanding and future directions.
Bisig et al., Haematologica 2023
DOI: 10.3324/haematol.2023.282716
Oh, brace yourselves, folks, for the riveting world of peripheral T- (and NK-) cell lymphomas (PTCL), where the most thrilling clinical party is happening in the lymph nodes. In this corner, we have the three main contenders: (i) the anaplastic large cell lymphomas (ALCL) that can’t decide if they like anaplastic lymphoma kinase (ALK) or not, (ii) the follicular helper T-cell lymphomas (TFHL) that are just dying to be unique, and (iii) the PTCL, not otherwise specified (NOS), because who doesn’t love a good mystery?
Now, hold onto your lab coats, because the 2022 classifications of lymphomas have had a makeover, thanks to some fancy genomic and molecular profiling. It turns out ALK-negative ALCL is the life of the genetic diversity party, with about 20-30% of cases showing off their DUSP22 rearrangements like it’s the latest fashion trend, complete with distinctive pathological and biological features.
And then there’s TFHL, strutting around with its cell-of-origin concept, acting like it’s either one disease or a clique of related entities. They’re all about those oncogenic pathways and love to gossip about their frequent recurrent epigenetic mutations and their ties to clonal hematopoiesis.
But wait, there’s more! It seems the cell-of-origin concept might also be the VIP pass to understanding the PTCL, NOS subgroups, with their cytotoxic and/or Th1 versus Th2 signatures. Because why have one signature when you can have two?
And let’s not forget the small but mighty group of primary nodal Epstein-Barr virus-positive lymphomas of T- or NK-cell derivation. They used to mingle with the PTCL, NOS crowd, but now they’ve been given their own table due to their distinctive features and notably aggressive behavior.
So, there you have it, a sizzling summary of the pathology and biology of nodal-based PTCL entities, with a side of recent findings and underlying oncogenic mechanisms. It’s like the ‘who’s who’ of lymphoma classifications, with a dash of molecular intrigue. Enjoy the read, and try not to get too caught up in the excitement.